硕世生物2025年预亏扩大，应收账款回收完成

Performance Overview - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -29.4 million and -44 million yuan, indicating an expanded loss compared to the previous year due to intensified industry competition, medical procurement, and VAT rate adjustments [2] Financial Status - The company announced the recovery of an accounts receivable over 5 years old amounting to 6.0994 million yuan, which is expected to have a positive impact on the financial status for 2026 [3] Company Developments - A temporary shareholders' meeting on January 5, 2026, approved the expansion of the business scope and amendments to the company's articles of association, which may involve business expansion [4] Stock Performance - As of February 11, 2026, the stock price was 68.75 yuan per share, down 2.01% for the day, with a net outflow of 4.7948 million yuan in main funds and a trading volume of 39.0139 million yuan. The financing balance as of February 2, 2026, was 392 million yuan, representing a high proportion of the circulating market value, at the 90th percentile level over the past year [5] Future Development - The actual controller renewed the "Joint Action Agreement" in December 2025, and the company's products were included in the World Health Organization's emergency use list, which may support long-term development [6]